New Fact Sheet .... http://files.shareholder.com/
Post# of 42
http://files.shareholder.com/downloads/OCLS/4..._Sheet.pdf
Ø Pure play dermatology-focused company, building multi-technology platform
Ø Products based on core Microcyn®Technology and in-licensing
Ø Addressable dermatitis market of 16.5 million prescriptions or ~$1.5+ billion, with good pricing flexibility and profitability
Ø Double-digit US product revenue growth providing affordable, unique & effective products –launching one per
quarter